The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
ConclusionsNiraparib (200 or 300 mg/day) was tolerable and had a favourable pharmacokinetic profile in Japanese patients with advanced solid tumours.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research